Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 28% Improvement Relative Risk Loucera et al. Vitamin C for COVID-19 Prophylaxis Is prophylaxis with vitamin C beneficial for COVID-19? Retrospective 15,968 patients in Spain (January - November 2020) Lower mortality with vitamin C (p=0.0018) Loucera et al., medRxiv, doi:10.1101/2022.08.14.22278751 Favors vitamin C Favors control
Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk
Loucera et al., medRxiv, doi:10.1101/2022.08.14.22278751 (Preprint)
Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests.., medRxiv, doi:10.1101/2022.08.14.22278751 (Preprint)
Aug 2022   Source   PDF  
  All Studies   Meta
Retrospective 15,968 COVID-19 hospitalized patients in Spain, showing lower mortality with existing use of several medications including metformin, HCQ, aspirin, vitamin D, vitamin C, and budesonide.
risk of death, 28.3% lower, HR 0.72, p = 0.002, treatment 840, control 15,128, Cox proportional hazards, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Loucera et al., 16 Aug 2022, retrospective, Spain, preprint, 8 authors, study period January 2020 - November 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: medRxiv preprint doi:; this version posted August 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk. Carlos Loucera1,2, Rosario Carmona1,2,3, Marina Esteban-Medina1,2, Gerrit Bostelmann1, Dolores Muñoyerro-Muñiz4, Román Villegas4, María Peña-Chilet1,2,3, Joaquin Dopazo1,2,3,5,* 1 Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Sevilla, 41013, Spain; 2 Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Seville, Spain; 3 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). FPS. Hospital Virgen del Rocio. 41013. Sevilla. Spain 4 Subdirección Técnica Asesora de Gestión de la Información. Servicio Andaluz de Salud. 41071, Sevilla, Spain; 5 FPS/ELIXIR-ES, Fundación Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain Abstract Despite the extensive vaccination campaigns in many countries, COVID-19 is still a major worldwide health problem because of its associated morbidity and mortality. Therefore, finding efficient treatments as fast as possible is a pressing need. Drug repurposing constitutes a convenient alternative when the need for new drugs in an unexpected medical scenario is urgent, as is the case with COVID-19. Using data from a central registry of electronic health records (the Andalusian Population Health Database, BPS), the effect of prior consumption of drugs for other indications previous to the hospitalization with respect to patient survival was studied on a retrospective cohort of 15,968 individuals, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Covariate-adjusted hazard ratios and analysis of lymphocyte progression curves support a significant association between consumption of 21 different drugs and better patient survival. Contrarily, one drug, furosemide, displayed a significant increase in patient mortality.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop